320 related articles for article (PubMed ID: 33068198)
1. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Garcia-Tejedor A; Fernandez-Gonzalez S; Ortega R; Gil-Gil M; Perez-Montero H; Fernandez-Montolí E; Stradella A; Recalde S; Soler T; Petit A; Bajen MT; Benitez A; Guma A; Campos M; Pla MJ; Martinez E; Laplana M; Pernas S; Perez-Sildekova D; Catala I; Ponce J; Falo C
Breast Cancer Res Treat; 2021 Feb; 185(3):657-666. PubMed ID: 33068198
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.
Fernandez-Gonzalez S; Falo C; Pla MJ; Verdaguer P; Nuñez D; Guma A; Soler T; Vethencourt A; Vázquez S; Fernandez-Montoli ME; Campos M; Pernas S; Gil M; Ponce J; Garcia-Tejedor A
Breast J; 2020 May; 26(5):888-896. PubMed ID: 32052521
[TBL] [Abstract][Full Text] [Related]
3. The use of axillary ultrasound (AUS) to assess the nodal status after neoadjuvant chemotherapy (NACT) in primary breast cancer patients.
Leinert E; Lukac S; Schwentner L; Coenen A; Fink V; Veselinovic K; Dayan D; Janni W; Friedl TWP
Surg Oncol; 2024 Feb; 52():102016. PubMed ID: 38056112
[TBL] [Abstract][Full Text] [Related]
4. Axillary lymph node dissection in triple-negative or HER2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
Guo X; Zhang J; Gong X; Wang J; Dai H; Jiao D; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; He J; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; Fan Z; Liu Z
Breast; 2024 Feb; 73():103671. PubMed ID: 38277714
[TBL] [Abstract][Full Text] [Related]
5. Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101629. PubMed ID: 34171793
[TBL] [Abstract][Full Text] [Related]
6. Nodal positivity in patients with clinically and radiologically node-negative breast cancer treated with neoadjuvant chemotherapy: multicentre collaborative study.
Zaborowski AM; Doogan K; Clifford S; Dowling G; Kazi F; Delaney K; Yadav H; Brady A; Geraghty J; Evoy D; Rothwell J; McCartan D; Heeney A; Barry M; Walsh SM; Stokes M; Kell MR; Allen M; Power C; Hill ADK; Connolly E; Alazawi D; Boyle T; Corrigan M; O'Leary P; Prichard RS
Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38055888
[TBL] [Abstract][Full Text] [Related]
7. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.
Zhang GC; Zhang YF; Xu FP; Qian XK; Guo ZB; Ren CY; Yao M
Curr Oncol; 2013 Jun; 20(3):e180-92. PubMed ID: 23737688
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in patients with breast cancer: Does response in the breast predict axillary node response?
Morgan C; Stringfellow TD; Rolph R; Kovacs T; Kothari A; Pinder SE; Hamed H; Sever AR
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):522-526. PubMed ID: 31740186
[TBL] [Abstract][Full Text] [Related]
9. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
10. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast.
Schwartz GF; Tannebaum JE; Jernigan AM; Palazzo JP
Cancer; 2010 Mar; 116(5):1243-51. PubMed ID: 20087958
[TBL] [Abstract][Full Text] [Related]
11. Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer.
Skarping I; Förnvik D; Zackrisson S; Borgquist S; Rydén L
Breast Cancer Res Treat; 2021 Aug; 189(1):131-144. PubMed ID: 34120224
[TBL] [Abstract][Full Text] [Related]
12. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of sentinel node biopsy in early breast cancer after neo-adjuvant chemotherapy: A prospective study.
Najim O; Dockx Y; Huyghe I; van den Wyngaert T; Papadimitriou K; Tjalma WAA; Huizing MT
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():108-111. PubMed ID: 30145524
[TBL] [Abstract][Full Text] [Related]
15. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer.
Ladak F; Chua N; Lesniak D; Ghosh S; Wiebe E; Yakimetz W; Rajaee N; Olson D; Peiris L
Can J Surg; 2022; 65(1):E89-E96. PubMed ID: 35135785
[TBL] [Abstract][Full Text] [Related]
16. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
[TBL] [Abstract][Full Text] [Related]
17. Axillary ultrasonography combined with pre-operative wire localisation of clipped node in nodal restaging after neoadjuvant chemotherapy in node positive breast cancer patients: a pilot study.
Pulappadi VP; Paul S; Hari S; Dhamija E; Manchanda S; Kataria K; Mathur S; Mani K; Gogia A; Deo S
Br J Radiol; 2021 Nov; 94(1127):20210788. PubMed ID: 34491822
[TBL] [Abstract][Full Text] [Related]
18. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
19. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
[TBL] [Abstract][Full Text] [Related]
20. Toward omitting sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with clinically node-negative breast cancer.
van der Noordaa MEM; van Duijnhoven FH; Cuijpers FNE; van Werkhoven E; Wiersma TG; Elkhuizen PHM; Winter-Warnars G; Dezentje V; Sonke GS; Groen EJ; Stokkel M; Vrancken Peeters MTFD
Br J Surg; 2021 Jun; 108(6):667-674. PubMed ID: 34157085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]